Across TCGA pan-cancer cohorts, MIR135B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR135B data layer compared with 17 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MIR135B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR135B expression acts as an unfavorable survival marker.
ACC are the cancer types where MIR135B Mutation most reproducibly stratifies survival.